- * - Male and female individuals 18 years of age and older at the time of enrollment who are mentally competent, willing and able to understand the nature and risks of the proposed study, and able to sign the consent form prior to study entry;
- * Individuals who are able to comply with all study procedures and requirements;
- * Healthy volunteers and volunteers specifically with underlying COPD, cardiovascular disease, diabetes mellitus, peripheral vascular disease, or renal impairment may be eligible;
- * Please contact the site for additional eligibility criteria.
Influenza, Human
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions
NCT02091908 | PHASE 3 | INTERVENTIONAL
Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects with and without underlying medical conditions.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
, Novartis Investigational Site
Berlin,Germany,10117
, Novartis Investigational Site
Dresden,Germany,01307
, Novartis Investigational Site
Hamburg,Germany,20359
, Novartis Investigational Site
Magdeburg,Germany,39120
, Novartis Investigational Site
Rostock,Germany,18055
, Novartis Investigational Site
Wuerzburg,Germany,97070
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov